Skip to main content

Month: April 2022

ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting

YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected for an oral presentation and six poster presentations at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held from April 23-26, 2022 in Lisbon, Portugal. The data being presented will feature exebacase, the Company’s Breakthrough Therapy designated product candidate currently being studied in a pivotal Phase 3 superiority design study, CF-370, an engineered lysin product candidate demonstrating...

Continue reading

Algoma Steel Announces Appointment of New CEO upon Retirement of Michael McQuade

Transition to take effect June 1st, 2022 SAULT STE. MARIE, Ontario, April 18, 2022 (GLOBE NEWSWIRE) — Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or the “Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today announced the appointment of Michael Garcia as Chief Executive Officer (“CEO”) effective June 1st, 2022 upon the retirement of current CEO Michael McQuade. Mr. McQuade will continue to serve on the Company’s board of directors (the “Board”) and Mr. Garcia will also join the Board concurrent with his appointment as CEO.   Andy Harshaw, Chairman of the Board, commented, “Mike McQuade has provided exemplary leadership through this transition period, taking Algoma from restructuring to a publicly listed company. He has set Algoma on secure footing as the company advances...

Continue reading

United States Lime Market to Reach USD 2.46 Billion by 2028 | U.S. Lime Industry Exhibiting a CAGR of 1.8% During Forecast Period

Companies covered in the U.S. lime market are Carmeuse, Lhoist Group, Graymont Limited, Mississippi Lime Company, United States Lime & Minerals Inc., Linwood Mining & Minerals Corporation, Minerals Technologies Inc., Cheney Lime & Cement Company, Pete Lien & Sons Inc., Valley Mineral LLC, Brookville Manufacturing and more players profiled. Pune, India, April 18, 2022 (GLOBE NEWSWIRE) — The U.S. lime market size is anticipated to reach USD 2.46 billion by 2028 and exhibit a CAGR of 1.8% during the forecast period. The rising demand for calcium hydroxide by the steel industry is anticipated to boost the market growth in the coming years. Fortune Business Insights has presented this information in its report titled “U.S. Lime Market, 2021-2028”. The market size stood at USD 2.14 billion in 2020 and USD 2.17 billion...

Continue reading

Toronto’s TTC awards contracts for up to 565 buses to NFI

NFI – New Flyer Xcelsior® Hybrid-Electric NFI – New Flyer Xcelsior® Hybrid-Electric busWINNIPEG, Manitoba, April 18, 2022 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that its subsidiary New Flyer Industries Canada ULC (“New Flyer”) has received new firm orders from the Toronto Transit Commission (“TTC”) for 134 Xcelsior® forty-foot hybrid-electric heavy-duty transit buses, and 68 Xcelsior sixty-foot hybrid-electric buses (136 equivalent units or “EUs”) for a total of 270 EUs. The two four-year contracts include options for up to an additional 263 forty-foot hybrid-electric buses and 100 sixty-foot buses, respectively. In total, NFI will add 733 EUs to its backlog from...

Continue reading

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America

•  Ocugen responsible for commercialization of COVAXIN™ in Mexico •  COVAXIN™, already authorized for emergency use in adults by health regulators in Mexico, has been submitted for Emergency Use Authorization for children aged 2-18 years MALVERN, Pa. and HYDERABAD, India, April 18, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, and Bharat Biotech (BBIL), a global leader in vaccine innovation, today announced that they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive territory to include commercialization of COVAXIN™ in Mexico. This gives Ocugen COVAXIN™ commercialization rights for all of North America. “We’re excited...

Continue reading

Greenwave Generates Revenues of $9.7 Million in Q1 2022

The Company is currently installing an additional automotive shredder and downstream system which is expected to double its processing capacity NORFOLK, Va., April 18, 2022 (GLOBE NEWSWIRE) — Greenwave Technology Solutions, Inc. (“Greenwave” or the “Company”) (OTCPink:GWAV) is pleased to report that it generated revenues of approximately $9.7 million during the first quarter of 2022, an increase of 63.5% from the $5.9 million in revenue Empire Services, Inc. (“Empire”) generated in the same period in 2021. Greenwave, through its subsidiary Empire, currently operates 11 metal recycling facilities in Virginia and North Carolina. Empire generated $27.75 million in revenue during the year ended December 31, 2021, up from $12.96 million during the year ended December 31, 2020, an increase of approximately 114%....

Continue reading

Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer

– Clinical update expected in second half of 2023 – CAMBRIDGE, Mass. and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the dosing of the first patient in the Phase 1 study evaluating BDTX-1535, a MasterKey inhibitor of epidermal growth factor receptor (EGFR) for the treatment of both non-small cell lung cancer (NSCLC) and glioblastoma (GBM)derived from Black Diamond’s MAP discovery engine. “The dosing of the first patient in our Phase 1 study of BDTX-1535, a next generation brain-penetrant inhibitor of oncogenic EGFR MasterKey mutations is an important step as we believe this program is uniquely positioned to address the existing unmet needs of EGFR mutant...

Continue reading

Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund

CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing). The R-Bridge Financing calls for an initial $15 million tranche within 15 days of the closing of the deal. Trevena will receive an additional $15 million upon the first commercial sale of OLINVYK® in China and $10 million upon achievement of either a financing or commercial milestone. R-Bridge Healthcare Fund is an affiliate of CBC Group, one of Asia’s largest and most active healthcare-dedicated investment firms focusing in three...

Continue reading

XPO Logistics Announces Openings of Two New Less-Than-Truckload Terminals

Expands LTL capacity in Southern California and Atlanta metro area GREENWICH, Conn., April 18, 2022 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading provider of freight transportation services, today announced the further expansion of its North American LTL network with the upcoming openings of two less-than-truckload (LTL) terminals: The Adelanto, California terminal will expand XPO’s footprint in San Bernardino County, where an influx of business development is driving demand for LTL services. The 51,500 sq. ft. facility includes 99 doors and a freight assembly center, and is expected to open this month. The Conley, Georgia terminal will be a sister site to XPO’s existing terminal and freight assembly center in Atlanta, adding pickup-and-delivery capacity in a high-volume metropolitan area. The 55,000 sq. ft....

Continue reading

Vivid Seats to Report First Quarter 2022 Financial Results

Prepared Remarks to be Webcast at 8:30 am ET CHICAGO, April 18, 2022 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ:SEAT) (“Vivid Seats” or the “Company”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, will report financial results for the first quarter 2022 on Tuesday, May 10, 2022, before the U.S. stock market opens. Management will discuss the results on a webcast at 8:30 a.m. ET. The live webcast and replay can be accessed at https://investors.vividseats.com/. About Vivid Seats Founded in 2001, Vivid Seats is a leading online ticket marketplace committed to becoming the ultimate partner for connecting fans to the live events, artists, and teams they love. Based on the belief that everyone should “Experience...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.